Matinas BioPharma Holdings, Inc.
MTNBAMEXHealthcare● Active
$0.83
+$0.04(+5.20%)
Market Cap$4609530
P/E Ratio—
52W High$3.09
52W Low$0.48
Matinas BioPharma Holdings, Inc. (MTNB) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
MTNB · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 8, 2026EPS Actual
-$0.30
Est. -$1.32 · +77.2%
Revenue
—
Est. $0.00B
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 8, 2026
After Market Close
▲ Beat EPS✓ 2-Quarter EPS Beat Streak
MTNB reports quarterly as a AMEX-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $0.59B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$0.59B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 13, 2026 | -$1.50 | — | — | — | $0.00B | — |
| ▲ Q2 FY2026 | May 8, 2026 | -$1.32 | -$0.30 | +77.2% | — | $0.00B | — |
| ▲ Q1 FY2026 | Mar 31, 2026 | -$0.78 | -$0.30 | +61.5% | — | $0.00B | — |
| — Q4 FY2025 | Nov 10, 2025 | — | -$0.40 | — | — | — | — |
| — Q3 FY2025 | Aug 14, 2025 | — | -$1.03 | — | — | — | — |
| ▼ Q2 FY2025 | Apr 15, 2025 | -$0.78 | -$1.68 | -115.4% | — | — | — |
| ▼ Q1 FY2025 | Mar 26, 2025 | -$0.78 | -$1.50 | -92.3% | $0.00B | — | — |
| ▲ Q4 FY2024 | Nov 13, 2024 | -$1.05 | -$0.85 | +19.1% | — | — | — |
Q3 FY2026
Aug 13, 2026
EPS Actual
—
EPS Est.
-$1.50
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 8, 2026Beat
EPS Actual
-$0.30
EPS Est.
-$1.32
EPS Surpr.
+77.2%
Revenue
—
Q1 FY2026
Mar 31, 2026Beat
EPS Actual
-$0.30
EPS Est.
-$0.78
EPS Surpr.
+61.5%
Revenue
—
Q4 FY2025
Nov 10, 2025
EPS Actual
-$0.40
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q3 FY2025
Aug 14, 2025
EPS Actual
-$1.03
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q2 FY2025
Apr 15, 2025Miss
EPS Actual
-$1.68
EPS Est.
-$0.78
EPS Surpr.
-115.4%
Revenue
—
Q1 FY2025
Mar 26, 2025Miss
EPS Actual
-$1.50
EPS Est.
-$0.78
EPS Surpr.
-92.3%
Revenue
$0.00B
Q4 FY2024
Nov 13, 2024Beat
EPS Actual
-$0.85
EPS Est.
-$1.05
EPS Surpr.
+19.1%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q1 FY2030 | $-0.78 | $-0.78 | $-0.78 | 1 |
| Q4 FY2029 | $-1.05 | $-1.05 | $-1.05 | 1 |
| Q3 FY2029 | $-1.25 | $-1.25 | $-1.25 | 1 |
| Q2 FY2029 | $-1.50 | $-1.50 | $-1.50 | 1 |
| Q1 FY2029 | $-1.50 | $-1.50 | $-1.50 | 1 |
| Q4 FY2028 | $-1.45 | $-1.45 | $-1.45 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q1 FY2030 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2029 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2029 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2029 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2029 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 8, 2026 | +77.2% | $0.65 | $0.64 | -1.08% |
| ▲ Q1 FY2026 | Mar 31, 2026 | +61.5% | $0.57 | $0.50 | -11.82% |
| — Q4 FY2025 | Nov 10, 2025 | — | $1.28 | $1.17 | -8.59% |
| — Q3 FY2025 | Aug 14, 2025 | — | $1.56 | $1.65 | +5.77% |
| ▼ Q2 FY2025 | Apr 15, 2025 | -115.4% | $0.58 | $0.58 | +0.00% |
| ▼ Q1 FY2025 | Mar 26, 2025 | -92.3% | $0.56 | $0.57 | +1.86% |
| ▲ Q4 FY2024 | Nov 13, 2024 | +19.1% | $0.75 | $0.71 | -4.83% |
| ▼ Q3 FY2024 | Aug 14, 2024 | -20.0% | $7.75 | $7.85 | +1.29% |
Q2 FY2026-1.08%
Report Date
May 8, 2026
EPS Beat/Miss
+77.2%
Price Before
$0.65
Price After
$0.64
Q1 FY2026-11.82%
Report Date
Mar 31, 2026
EPS Beat/Miss
+61.5%
Price Before
$0.57
Price After
$0.50
Q4 FY2025-8.59%
Report Date
Nov 10, 2025
EPS Beat/Miss
—
Price Before
$1.28
Price After
$1.17
Q3 FY2025+5.77%
Report Date
Aug 14, 2025
EPS Beat/Miss
—
Price Before
$1.56
Price After
$1.65
Q2 FY2025+0.00%
Report Date
Apr 15, 2025
EPS Beat/Miss
-115.4%
Price Before
$0.58
Price After
$0.58
Q1 FY2025+1.86%
Report Date
Mar 26, 2025
EPS Beat/Miss
-92.3%
Price Before
$0.56
Price After
$0.57
Q4 FY2024-4.83%
Report Date
Nov 13, 2024
EPS Beat/Miss
+19.1%
Price Before
$0.75
Price After
$0.71
Q3 FY2024+1.29%
Report Date
Aug 14, 2024
EPS Beat/Miss
-20.0%
Price Before
$7.75
Price After
$7.85
Avg Beat Reaction-5.91%
Avg Miss Reaction+1.05%
Beat Rate3 / 8 quarters
Largest Move-11.82% (Q1 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: MTNB ends December
Matinas BioPharma Holdings, Inc. (MTNB) most recently reported earnings on May 8, 2026 for Q2 FY2026, posting EPS of $-0.30 — beating the analyst consensus of $-1.32 by +77.2%. MTNB has beaten EPS estimates for 2 consecutive quarters. The next MTNB earnings date is expected around September 1, 2026.
Each quarter, investors track MTNB earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. MTNB revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
MTNB's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
MTNB earnings · 5 questionsMatinas BioPharma Holdings, Inc.'s next earnings report is expected around September 1, 2026. MTNB typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; MTNB historically reports after market close (AMC).
MTNB earnings datewhen is MTNB earningsMTNB next earnings datewhen does MTNB report earningsMTNB earnings calendar
▸ Source: FMP · Matinas BioPharma Holdings, Inc. SEC filings · US GAAP · Matinas BioPharma Holdings, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026